Dosage of Ceftriaxone APP in details
Intended for IV administration only.
B Braun Ceftriaxone APP and calcium-containing solutions, including continuous calcium-containing infusions eg, parenteral nutrition, should not be mixed or co-administered to any patient irrespective of age, even via different infusion lines at different sites.
Treatment of Skin and Skin Structure Infections: Recommended Total Daily Dose: 50-75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 g.
Treatment of Serious Miscellaneous Infections Other than Meningitis: Recommended Total Daily Dose: 50-75 mg/kg, given in divided doses every 12 hrs. The total daily dose should not exceed 2 g.
Treatment of Meningitis: Recommended Initial Therapeutic Dose: 100 mg/kg (not to exceed 4 g). Thereafter, a total daily dose of 100 mg/kg/day (not to exceed 4 g daily) is recommended. The daily dose may be administered once a day (or in equally divided doses every 12 hrs). The usual duration of therapy is 7-14 days.
Adults: Usual Daily Dose: 1-2 g given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. The total daily dose should not exceed 4 g.
If Chlamydia trachomatis is a suspected pathogen, appropriate antichlamydial coverage should be added, because Ceftriaxone APP sodium has no activity against this organism.
For preoperative use (surgical prophylaxis), a single dose of 1 g administered IV ½-2 hrs before surgery is recommended.
Generally, B Braun Ceftriaxone APP therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4-14 days; in complicated infections, longer therapy may be required.
When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days.
Children: B Braun Ceftriaxone APP in the Duplex container is designed to deliver a 1 or 2 g dose of Ceftriaxone APP. To prevent unintentional overdose, B Braun Ceftriaxone APP should not be used in pediatric patients who require less than the full adult dose of Ceftriaxone APP.
Neonates: Hyperbilirubinemic neonates, especially prematures, should not be treated with B Braun Ceftriaxone APP.
Hepatic and Renal Impairment: No dosage adjustment is necessary for patients with impairment of renal or hepatic function; however, blood levels should be monitored in patients with severe renal impairment (eg, dialysis patients) and in patients with both renal and hepatic dysfunctions.
Administration: Directions for Use: B Braun Ceftriaxone APP should be administered IV by infusion over a period of 30 min.
Vancomycin, amsacrine, aminoglycosides and fluconazole are physically incompatible with Ceftriaxone APP in admixtures. When any of these drugs are to be administered concomitantly with Ceftriaxone APP by intermittent IV infusion, it is recommended that they be given sequentially, with thorough flushing of the IV lines (with one of the compatible fluids) between the administrations.
B Braun Ceftriaxone APP should not be physically mixed with or piggybacked into solutions containing other antimicrobial drugs due to possible incompatibility.
After the indicated stability time periods, unused portions of solutions should be discarded.
What other drugs will affect Ceftriaxone APP?
There may be other drugs that can interact with Ceftriaxone APP. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Ceftriaxone APP interactions
No impairment of renal function has so far been observed after concurrent administration of large doses of Ceftriaxone APP and potent diuretics (eg, furosemide). There is no evidence that Ceftriaxone APP increases renal toxicity of aminoglycosides. No effect similar to that of disulfiram has been demonstrated after ingestion of alcohol subsequent to the administration of Ceftriaxone APP. Ceftriaxone APP does not contain an N-methylthiotetrazole moiety associated with possible ethanol intolerance and bleeding problems of certain other cephalosporins. The elimination of Ceftriaxone APP is not altered by probenecid. In an in vitro study, antagonistic effects have been observed with the combination of chloramphenicol and Ceftriaxone APP.
Do not use diluents containing calcium eg, Ringer's or Hartmann's solution, to reconstitute Ceftriaxone APP vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of Ceftriaxone APP-calcium can also occur when Ceftriaxone APP is mixed with calcium-containing solutions in the same IV administration line.
Ceftriaxone APP must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions eg, parenteral nutrition via a Y-site. However, in patients other than neonates, Ceftriaxone APP and calcium-containing solutions may be administered sequentially of one another, if the infusion lines are thoroughly flushed between infusions with a compatible fluid. In vitro studies using adult and neonatal plasma from umbilical cord, blood demonstrated that neonates have an increased risk of precipitation of Ceftriaxone APP-calcium.
Based on literature reports, Ceftriaxone APP is incompatible with amsacrine, vancomycin, fluconazole and aminoglycosides.
In patients treated with Ceftriaxone APP, the Coombs' test may in rare cases be false-positive. Ceftriaxone APP, like other antibiotics, may result in false-positive tests for galactosemia. Likewise, non-enzymatic methods for glucose determination in urine may yield false-positive results. For this reason, glucose level determination in urine during therapy with Ceftriaxone APP should be carried out enzymatically.
Ceftriaxone APP may adversely affect the efficacy of oral hormonal contraceptives.
Consequently, it is advisable to use supplementary (nonhormonal) contraceptive measures during treatment and in the month following treatment.
Incompatibilities: Solutions containing Ceftriaxone APP should not be mixed with or added to other agents. In particular, diluents containing calcium (eg, Ringer's or Hartmann's solution), should not be used to reconstitute Ceftriaxone APP vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Ceftriaxone APP must not be mixed or administered simultaneously with calcium-containing solutions. Based on literature reports, Ceftriaxone APP is not compatible with amsacrine, vancomycin, fluconazole and aminoglycosides.
References
- DailyMed. "CEFTRIAXONE SODIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "75J73V1629: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Ceftriaxone APP are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ceftriaxone APP. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
